Filgrastim biosimilar - Merck

Drug Profile

Filgrastim biosimilar - Merck

Alternative Names: INS-19; MK-4214

Latest Information Update: 29 Aug 2013

Price : $50

At a glance

  • Originator Insmed
  • Developer Insmed; Merck & Co
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Haematopoietic cell growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Neutropenia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 29 Aug 2013 No development reported - Phase-I for Neutropenia in USA (SC)
  • 29 Aug 2013 No development reported - Phase-III for Neutropenia in Latvia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top